FDA accepts for priority review new drug application for budesonide oral suspension (Eohilia) for treatment of eosinophilic esophagitis (EoE)

Eohilia is a mucoadherent topically active oral viscous formulation of budesonide, formulated specifically to treat localised oesophageal inflammation caused by EoE, a chronic, immune-mediated, inflammatory disease, which can lead to difficulty swallowing, vomiting and heartburn.

SPS commentary:

In the UK, the only licensed budesonide product for the treatment of eosinophilic esophagitis is Jorveza, which comes as an orodispersible tablet.

Biospace Inc.